Director/PDMR Shareholding

RNS Number : 4011Q
GlaxoSmithKline PLC
18 February 2019
 

GlaxoSmithKline plc (the 'Company')

Shares sold to meet tax liabilities

Following the vesting of awards granted in 2016 under the GlaxoSmithKline 2009 Performance Share Plan on 14 February 2019 and as notified on 15 February 2019, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities ('PDMRs') in Ordinary Shares and in American Depositary Shares ('ADSs') of the Company arising from the sale of Ordinary Shares or ADSs to meet tax liabilities.

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

66,159

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

38,633

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

   

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

  

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$41.1716

2,311

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

15,937

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$41.1716

16,675

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

28,009

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharma Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

3,873

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

35,253

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

20,283

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8462

3,873

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQVLFFKLFFBBB

Companies

GSK (GSK)
UK 100

Latest directors dealings